ADAMTS9-AS2 and breast carcinoma: ADAMTS9-AS2 is downregulated in tamoxifen-resistant cells derived from MCF7, and downregulation of ADAMTS9-AS2 is also observed in breast cancer tissues, especially in breast tumors with grade III–IV or a tumor size larger than 2 cm [45].